Pharmaceuticals

Sage and Biogen halt Phase 2 trial of new drug after failure to show significant improvement in treating essential tremor

bexib
By bexib 0 Min Read

Going forward, Sage Therapeutics and Biogen plan to discontinue further clinical development of SAGE-324 for essential tremor.

You Might Also Like

How Pharma Marketers Can Succeed in a Cookie-Free Era: Q&A with David Minkin

Huntington’s disease research and development is picking up after some disappointments

FDA Approves Regeneron and Sanofi’s Kevzara for Treatment of Patients with Active Polyarticular Juvenile Idiopathic Arthritis

Rowing team completes 2,800-mile journey to raise funds for Parkinson’s research

Brave biotech threatens Pfizer’s dominance of Prevnar vaccine market

Share This Article
Previous Article Measuring inequality from multiple angles
Next Article Delta Air Lines expects flight disruptions to ease and operations to return to normal by Thursday Reuters – Investorempires.com
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

dtcpay and BNB Chain power the ecosystem for real-world stablecoin usage
Fintech
The Path Forward – Machine Insider
Manufacturing
How India’s UPI makeover and WhatsApp Pay expansion will transform banking
Fintech
Navigating innovation and sustainability in metal cutting
Manufacturing